BIOGEN INC. Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
BIOGEN INC. (BIIB) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of -$7.80 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-10-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2024-10-30
- BIOGEN INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2024-09-30 was -$7.80M, a 966.67% decline year-over-year.
- BIOGEN INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2024-06-30 was $16.70M, a 1013.33% increase year-over-year.
- BIOGEN INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2024-03-31 was -$6.10M, a 180.26% decline year-over-year.
- BIOGEN INC. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2023-09-30 was $900.00K, a 90.63% decline year-over-year.
- BIOGEN INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2022 was $87.00M, a 35.12% decline from fiscal 2021.
- BIOGEN INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2021 was $134.10M.
- BIOGEN INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2020 was -$145.60M, a 163.08% decline from fiscal 2019.
- BIOGEN INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2019 was $230.80M, a 682.37% increase from fiscal 2018.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 3 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 9 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$7.80M 10-Q · filed 2024-10-30 | $8.90M derived: sum of 2 quarters · filed 2024-10-30 | $2.80M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $16.70M 10-Q · filed 2024-08-01 | $10.60M 10-Q · filed 2024-08-01 | ||
| 2024-03-31 | -$6.10M 10-Q · filed 2024-04-24 | |||
| 2023-09-30 | $900.00K 10-Q · filed 2024-10-30 | $2.40M derived: sum of 2 quarters · filed 2024-10-30 | $10.00M 10-Q · filed 2024-10-30 | $56.60M derived: sum of 4 quarters · filed 2024-10-30 |
| 2023-06-30 | $1.50M 10-Q · filed 2024-08-01 | $9.10M 10-Q · filed 2024-08-01 | $55.70M derived: sum of 3 quarters · filed 2024-08-01 | $65.30M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $7.60M 10-Q · filed 2024-04-24 | $54.20M derived: sum of 2 quarters · filed 2024-04-24 | $63.80M derived: sum of 3 quarters · filed 2024-04-24 | $86.20M derived: sum of 4 quarters · filed 2024-04-24 |
| 2022-12-31 | $46.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $56.20M derived: sum of 2 quarters · filed 2023-11-08 | $78.60M derived: sum of 3 quarters · filed 2023-11-08 | $87.00M 10-K · filed 2023-02-15 |
| 2022-09-30 | $9.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $32.00M derived: sum of 2 quarters · filed 2023-11-08 | $40.40M 10-Q · filed 2023-11-08 | $75.10M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $22.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25 | $30.80M 10-Q · filed 2023-07-25 | $65.50M derived: sum of 3 quarters · filed 2023-07-25 | $86.70M derived: sum of 4 quarters · filed 2023-07-25 |
| 2022-03-31 | $8.40M 10-Q · filed 2023-04-25 | $43.10M derived: sum of 2 quarters · filed 2023-04-25 | $64.30M derived: sum of 3 quarters · filed 2023-04-25 | $39.20M derived: sum of 4 quarters · filed 2023-04-25 |
| 2021-12-31 | $34.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $55.90M derived: sum of 2 quarters · filed 2023-02-15 | $30.80M derived: sum of 3 quarters · filed 2023-02-15 | $134.10M 10-K · filed 2023-02-15 |
| 2021-09-30 | $21.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | -$3.90M derived: sum of 2 quarters · filed 2022-10-25 | $99.40M 10-Q · filed 2022-10-25 | $8.20M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | -$25.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | $78.20M 10-Q · filed 2022-07-20 | -$13.00M derived: sum of 3 quarters · filed 2023-02-15 | -$64.10M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $103.30M 10-Q · filed 2022-05-03 | $12.10M derived: sum of 2 quarters · filed 2023-02-15 | -$39.00M derived: sum of 3 quarters · filed 2023-02-15 | -$43.00M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | -$91.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$142.30M derived: sum of 2 quarters · filed 2023-02-15 | -$146.30M derived: sum of 3 quarters · filed 2023-02-15 | -$145.60M 10-K · filed 2023-02-15 |
| 2020-09-30 | -$51.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-20 | -$55.10M derived: sum of 2 quarters · filed 2021-10-20 | -$54.40M 10-Q · filed 2021-10-20 | -$57.30M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-06-30 | -$4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-22 | -$3.30M 10-Q · filed 2021-07-22 | -$6.20M derived: sum of 3 quarters · filed 2022-02-03 | $191.50M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-03-31 | $700.00K 10-Q · filed 2021-04-22 | -$2.20M derived: sum of 2 quarters · filed 2022-02-03 | $195.50M derived: sum of 3 quarters · filed 2022-02-03 | $194.20M derived: sum of 4 quarters · filed 2022-02-03 |
| 2019-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $194.80M derived: sum of 2 quarters · filed 2022-02-03 | $193.50M derived: sum of 3 quarters · filed 2022-02-03 | $230.80M 10-K · filed 2022-02-03 |
| 2019-09-30 | $197.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21 | $196.40M derived: sum of 2 quarters · filed 2020-10-21 | $233.70M 10-Q · filed 2020-10-21 | $251.40M derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-06-30 | -$1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-22 | $36.00M 10-Q · filed 2020-07-22 | $53.70M derived: sum of 3 quarters · filed 2021-02-03 | $58.30M derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-03-31 | $37.30M 10-Q · filed 2020-04-23 | $55.00M derived: sum of 2 quarters · filed 2021-02-03 | $59.60M derived: sum of 3 quarters · filed 2021-02-03 | $91.20M derived: sum of 4 quarters · filed 2021-02-03 |
| 2018-12-31 | $17.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $22.30M derived: sum of 2 quarters · filed 2021-02-03 | $53.90M derived: sum of 3 quarters · filed 2021-02-03 | $29.50M 10-K · filed 2021-02-03 |
| 2018-09-30 | $4.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22 | $36.20M derived: sum of 2 quarters · filed 2019-10-22 | $11.80M 10-Q · filed 2019-10-22 | -$6.10M derived: sum of 4 quarters · filed 2020-02-06 |
| 2018-06-30 | $31.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $7.20M 10-Q · filed 2019-07-24 | -$10.70M derived: sum of 3 quarters · filed 2020-02-06 | -$20.10M derived: sum of 4 quarters · filed 2020-02-06 |
| 2018-03-31 | -$24.40M 10-Q · filed 2019-04-24 | -$42.30M derived: sum of 2 quarters · filed 2020-02-06 | -$51.70M derived: sum of 3 quarters · filed 2020-02-06 | -$68.10M derived: sum of 4 quarters · filed 2020-02-06 |
| 2017-12-31 | -$17.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | -$27.30M derived: sum of 2 quarters · filed 2020-02-06 | -$43.70M derived: sum of 3 quarters · filed 2020-02-06 | -$42.70M 10-K · filed 2020-02-06 |
| 2017-09-30 | -$9.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23 | -$25.80M derived: sum of 2 quarters · filed 2018-10-23 | -$24.80M 10-Q · filed 2018-10-23 | -$39.10M derived: sum of 4 quarters · filed 2019-02-06 |
| 2017-06-30 | -$16.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-24 | -$15.40M 10-Q · filed 2018-07-24 | -$29.70M derived: sum of 3 quarters · filed 2019-02-06 | -$53.10M derived: sum of 4 quarters · filed 2019-02-06 |
| 2017-03-31 | $1.00M 10-Q · filed 2018-04-24 | -$13.30M derived: sum of 2 quarters · filed 2019-02-06 | -$36.70M derived: sum of 3 quarters · filed 2019-02-06 | -$64.90M derived: sum of 4 quarters · filed 2019-02-06 |
| 2016-12-31 | -$14.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | -$37.70M derived: sum of 2 quarters · filed 2019-02-06 | -$65.90M derived: sum of 3 quarters · filed 2019-02-06 | -$92.50M 10-K · filed 2019-02-06 |
| 2016-09-30 | -$23.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-24 | -$51.60M derived: sum of 2 quarters · filed 2017-10-24 | -$78.20M 10-Q · filed 2017-10-24 | -$91.40M derived: sum of 4 quarters · filed 2018-02-01 |
| 2016-06-30 | -$28.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-25 | -$54.80M 10-Q · filed 2017-07-25 | -$68.00M derived: sum of 3 quarters · filed 2018-02-01 | -$81.60M derived: sum of 4 quarters · filed 2018-02-01 |
| 2016-03-31 | -$26.60M 10-Q · filed 2017-04-25 | -$39.80M derived: sum of 2 quarters · filed 2018-02-01 | -$53.40M derived: sum of 3 quarters · filed 2018-02-01 | -$43.80M derived: sum of 4 quarters · filed 2018-02-01 |
| 2015-12-31 | -$13.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | -$26.80M derived: sum of 2 quarters · filed 2018-02-01 | -$17.20M derived: sum of 3 quarters · filed 2018-02-01 | $6.50M 10-K · filed 2018-02-01 |
| 2015-09-30 | -$13.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | -$4.00M derived: sum of 2 quarters · filed 2016-10-26 | $19.70M 10-Q · filed 2016-10-26 | $11.60M derived: sum of 4 quarters · filed 2017-02-02 |
| 2015-06-30 | $9.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-21 | $33.30M 10-Q · filed 2016-07-21 | $25.20M derived: sum of 3 quarters · filed 2017-02-02 | $16.70M derived: sum of 4 quarters · filed 2017-02-02 |
| 2015-03-31 | $23.70M 10-Q · filed 2016-04-21 | $15.60M derived: sum of 2 quarters · filed 2017-02-02 | $7.10M derived: sum of 3 quarters · filed 2017-02-02 | $3.40M derived: sum of 4 quarters · filed 2017-02-02 |
| 2014-12-31 | -$8.10M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | -$16.60M derived: sum of 2 quarters · filed 2017-02-02 | -$20.30M derived: sum of 3 quarters · filed 2017-02-02 | -$19.10M 10-K · filed 2017-02-02 |
| 2014-09-30 | -$8.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-21 | -$12.20M derived: sum of 2 quarters · filed 2015-10-21 | -$11.00M 10-Q · filed 2015-10-21 | -$9.20M derived: sum of 4 quarters · filed 2016-02-03 |
| 2014-06-30 | -$3.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-24 | -$2.50M 10-Q · filed 2015-07-24 | -$700.00K derived: sum of 3 quarters · filed 2016-02-03 | $17.90M derived: sum of 4 quarters · filed 2016-02-03 |
| 2014-03-31 | $1.20M 10-Q · filed 2015-04-24 | $3.00M derived: sum of 2 quarters · filed 2016-02-03 | $21.60M derived: sum of 3 quarters · filed 2016-02-03 | $34.50M derived: sum of 4 quarters · filed 2016-02-03 |
| 2013-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $20.40M derived: sum of 2 quarters · filed 2016-02-03 | $33.30M derived: sum of 3 quarters · filed 2016-02-03 | $24.30M 10-K · filed 2016-02-03 |
| 2013-09-30 | $18.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-22 | $31.50M derived: sum of 2 quarters · filed 2014-10-22 | $22.50M 10-Q · filed 2014-10-22 | |
| 2013-06-30 | $12.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-23 | $3.90M 10-Q · filed 2014-07-23 | ||
| 2013-03-31 | -$9.00M 10-Q · filed 2014-04-23 | |||
| 2012-12-31 | $3.80M 10-K · filed 2015-02-04 | |||
| 2011-12-31 | -$2.50M 10-K · filed 2014-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |